VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
HCA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HCAHCA Healthcare, Inc.
$391.68$86.9B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksHCAFinancials

HCA Healthcare, Inc. (HCA) Financials

30Y historyFree accessUpdated daily

Revenue growth has slowed to 4.3% in 2026Q1, while gross margins experienced a sharp contraction to 15.0% compared to the 41% range maintained throughout 2025.

HCA Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue76.39B75.6B70.6B64.97B60.23B58.75B51.53B51.34B46.68B43.61B41.49B39.68B36.92B34.18B33.01B32.51B30.68B30.05B28.37B26.86B25.48B24.45B23.5B21.81B19.73B17.95B16.67B16.66B18.68B18.82B19.91B
Revenue Growth %6.71%7.08%8.67%7.86%2.52%14.01%0.38%9.98%7.02%5.12%4.57%7.48%8%3.54%1.56%5.94%2.1%5.91%5.64%5.42%4.18%4.06%7.77%10.54%9.89%7.7%0.08%-10.83%-0.73%-5.47%12.51%
Cost of Goods Sold49.71B44.23B41.92B39.39B37.06B36.26B8.37B8.48B7.72B7.32B6.93B6.64B6.26B5.97B5.72B5.18B4.96B4.87B4.62B4.39B4.32B4.13B3.9B00000007.54B
COGS % of Revenue-58.5%59.38%60.63%61.52%61.72%16.24%16.52%16.55%16.77%16.71%16.73%16.96%17.47%17.32%15.93%16.17%16.2%16.28%16.36%16.96%16.87%16.6%-------37.87%
Gross Profit26.68B31.37B28.68B25.58B23.18B22.49B43.16B42.85B38.95B36.3B34.56B33.04B30.66B28.21B27.3B24.5B23.07B25.18B23.75B22.46B21.16B20.33B19.6B000000011.25B
Gross Margin %34.92%41.5%40.62%39.37%38.48%38.28%83.76%83.48%83.45%83.23%83.29%83.27%83.04%82.53%82.68%75.38%75.2%83.8%83.72%83.64%83.04%83.13%83.4%-------56.49%
Gross Profit Growth %-9.4%12.12%10.36%3.05%-47.89%0.72%10.02%7.31%5.04%4.59%7.78%8.66%3.36%11.4%6.19%-8.38%6.02%5.75%6.18%4.06%3.71%--------100%8.14%
Operating Expenses14.7B19.41B18.13B15.95B14.12B12.81B35.9B35.64B32.31B30.24B28.36B27.07B25.09B23.42B22.48B20.16B18.91B21.38B20.82B19.51B18.32B17.43B16.89B19.01B17.68B15.73B117M220M1.79B17.65B8.35B
OpEx % of Revenue-25.67%25.68%24.55%23.45%21.81%69.67%69.42%69.22%69.34%68.35%68.24%67.96%68.52%68.09%62.03%61.63%71.15%73.37%72.65%71.9%71.25%71.84%87.17%89.61%87.61%0.7%1.32%9.58%93.78%41.93%
Selling, General & Admin16.14B8B31.17B29.49B27.68B26.78B23.87B23.56B21.43B20.06B18.9B18.11B16.64B15.65B15.09B13.44B12.48B11.96B11.44B10.71B10.41B9.93B9.42B8.68B7.95B7.28B6.64B6.75B7.81B7.63B7.21B
SG&A % of Revenue-10.58%44.15%45.39%45.96%45.58%46.33%45.89%45.9%45.99%45.55%45.66%45.08%45.77%45.71%41.35%40.69%39.79%40.32%39.89%40.86%40.6%40.08%39.81%40.31%40.54%39.83%40.52%41.81%40.55%36.19%
Research & Development0000000000000000000000000000000
R&D % of Revenue-------------------------------
Other Operating Expenses011.41B-13.04B-13.54B-13.56B-13.96B12.03B12.08B10.89B10.18B9.46B8.96B8.45B7.77B7.39B6.72B6.42B9.43B9.38B8.8B7.91B7.5B7.47B10.33B9.73B8.45B-6.52B-6.53B-6.02B10.02B1.14B
Operating Income11.97B11.96B10.55B9.63B9.05B9.68B7.26B7.22B6.64B6.06B6.2B5.96B5.57B4.79B4.82B4.34B4.17B3.8B2.94B2.95B2.84B2.9B2.72B2.8B2.05B2.23B16.55B16.44B16.89B1.17B2.9B
Operating Margin %15.67%15.83%14.94%14.82%15.03%16.47%14.09%14.06%14.23%13.89%14.94%15.03%15.07%14.02%14.59%13.35%13.57%12.65%10.34%10.99%11.13%11.87%11.56%12.83%10.39%12.39%99.3%98.68%90.42%6.22%14.56%
Operating Income Growth %-13.44%9.56%6.34%-6.46%33.27%0.61%8.67%9.66%-2.27%3.91%7.19%16.13%-0.5%11.02%4.15%9.58%29.51%-0.58%4.09%-2.34%6.92%-2.9%36.51%-7.91%-86.56%0.71%-2.69%1342.53%-59.59%9.61%
EBITDA15.57B15.49B13.86B12.7B12.02B12.53B9.98B9.81B8.92B8.19B8.16B7.87B7.38B6.54B6.5B5.8B5.59B5.23B4.35B4.38B4.23B4.28B3.97B3.91B3.06B3.27B17.59B17.53B18.14B2.41B4.05B
EBITDA Margin %20.38%20.49%19.63%19.55%19.96%21.33%19.37%19.12%19.11%18.77%19.68%19.83%20%19.15%19.67%17.85%18.21%17.39%15.33%16.3%16.59%17.49%16.88%17.92%15.51%18.23%105.49%105.25%97.1%12.8%20.36%
EBITDA Growth %9.47%11.75%9.09%5.67%-4.06%25.52%1.72%10.02%8.94%0.29%3.75%6.55%12.83%0.77%11.92%3.88%6.89%20.11%-0.62%3.57%-1.19%7.87%1.46%27.79%-6.54%-81.39%0.31%-3.35%652.97%-40.56%11.81%
D&A (Non-Cash Add-back)3.59B3.52B3.31B3.08B2.97B2.85B2.72B2.6B2.28B2.13B1.97B1.9B1.82B1.75B1.68B1.47B1.42B1.43B1.42B1.43B1.39B1.37B1.25B1.11B1.01B1.05B1.03B1.09B1.25B1.24B1.16B
EBIT12.08B12.08B10.58B9.64B10.32B11.4B7.01B7.07B7.09B6.07B6.52B5.62B5.22B4.79B4.69B5.6B4.33B3.99B3.19B3.4B2.62B2.8B2.54B2.8B2.05B2.23B16.55B16.44B16.89B1.17B2.9B
Net Interest Income-2.29B-2.25B-2.06B-1.94B-1.74B-1.53B-1.56B-1.84B-1.76B-1.67B-1.6B-1.54B-1.61B-1.72B-1.68B-1.7B-2.1B-1.64B-2.02B-2.21B-955M-655M-563M00000000
Interest Income0000000000000000000000000000000
Interest Expense2.29B2.25B2.06B1.94B1.74B1.53B1.56B1.84B1.76B1.67B1.6B1.54B1.61B1.72B1.68B1.7B2.1B1.64B2.02B2.21B955M655M563M00000000
Other Income/Expense-2.18B-2.13B-2.02B-1.92B-473M155M-1.83B-1.97B-1.31B-1.68B-1.39B-2.01B-2.08B-1.85B-1.92B-777M-1.93B-1.8B-1.76B-1.76B-1.17B-755M-743M-641M-594M-720M-16.04B-15.21B-15.81B-783M-456M
Pretax Income9.79B9.83B8.52B7.71B8.58B9.83B5.43B5.24B5.33B4.38B4.81B3.96B3.48B2.95B2.89B3.56B2.23B2B1.17B1.19B1.66B2.15B1.97B2.16B1.46B1.5B516M1.23B1.08B388M2.44B
Pretax Margin %12.82%13.01%12.07%11.86%14.24%16.74%10.54%10.22%11.43%10.04%11.59%9.97%9.43%8.62%8.77%10.95%7.27%6.66%4.12%4.43%6.52%8.79%8.39%9.89%7.37%8.38%3.1%7.37%5.79%2.06%12.27%
Income Tax1.98B2.05B1.87B1.61B1.75B2.11B1.04B1.1B946M1.64B1.38B1.26B1.11B950M888M719M658M627M268M316M626M725M727M824M622M602M297M570M549M206M981M
Effective Tax Rate %20.2%20.85%21.89%20.96%20.35%21.48%19.21%20.96%17.73%37.39%28.65%31.87%31.83%32.25%30.68%20.19%29.49%31.32%22.91%26.55%37.67%33.74%36.85%38.22%42.75%40%57.56%46.45%50.79%53.09%40.17%
Net Income6.79B6.78B5.76B5.24B5.64B6.96B3.75B3.5B3.79B2.22B2.89B2.13B1.88B1.56B1.6B2.46B1.21B1.05B673M874M1.04B1.42B1.25B1.33B833M886M292M740M471M-305M1.5B
Net Margin %8.89%8.97%8.16%8.07%9.37%11.84%7.28%6.83%8.11%5.08%6.97%5.37%5.08%4.55%4.86%7.58%3.93%3.51%2.37%3.25%4.07%5.82%5.3%6.11%4.22%4.94%1.75%4.44%2.52%-1.62%7.56%
Net Income Growth %17.56%17.78%9.88%-7.11%-18.88%85.3%7.1%-7.45%70.89%-23.32%35.74%13.55%20.5%-3.05%-34.89%104.23%14.52%56.61%-23%-15.64%-27.25%14.29%-6.46%59.9%-5.98%203.42%-60.54%57.11%254.43%-120.27%56.61%
Net Income (Continuing)7.81B7.78B6.66B6.09B6.83B7.72B4.39B4.14B4.39B2.74B3.43B2.7B2.37B2B2.01B2.84B1.57B1.38B902M874M1.04B1.42B1.25B1.48B981M903M208M683M401M182M1.46B
Discontinued Operations0000000000000000000000000000-153M-431M44M
Minority Interest3.33B3.26B3.05B2.83B2.69B2.42B2.32B2.24B2.03B1.81B1.67B1.55B1.4B1.34B1.32B1.24B1.13B1.01B995M938M907M828M809M680M611M563M572M763M765M836M836M
EPS (Diluted)29.9828.3822.0018.9619.1521.1610.9310.0710.665.957.304.994.163.373.494.972.763.021.932.512.533.182.582.611.591.650.401.110.73-0.462.22
EPS Growth %29.24%29%16.03%-0.99%-9.5%93.6%8.54%-5.53%79.16%-18.49%46.29%19.95%23.44%-3.44%-29.78%80.07%-8.61%56.48%-23.11%-0.79%-20.44%23.26%-1.15%64.15%-3.64%312.5%-63.96%52.05%258.7%-120.72%55.24%
EPS (Basic)-28.6222.2719.2419.4421.5111.0810.2711.046.337.805.344.463.543.625.172.833.081.972.562.573.242.622.661.631.690.391.120.73-0.462.24
Diluted Shares Outstanding226.65M230.71M261.81M276.41M294.67M328.75M345.37M348.23M355.3M372.22M395.85M426.72M450.35M461.91M459.4M495.94M437.35M348.71M348.71M348.71M410.2M447.5M483.66M510.34M523.9M536.97M553.93M666.67M645.21M663.04M677.93M
Basic Shares Outstanding226.65M230.71M258.6M272.4M290.35M323.31M339.43M341.21M342.9M350.09M370.54M398.74M420.48M439.6M443.2M476.61M426.42M341.93M341.93M341.93M403.4M440.02M475.62M500.75M511.04M524.26M547.51M660.71M645.21M663.04M671.88M
Dividend Payout Ratio-10.01%11.98%12.61%11.57%8.97%4.08%15.69%12.86%---0.37%1.03%196.14%1.26%352.69%---19.4%18.12%15.97%2.93%4.8%4.74%15.07%---3.59%

Key Metrics

Growth RegimeDecelerating
ProfitabilityModerate
Balance SheetHealthy
Cash FlowStable
Top Statement Risk

Regulatory reimbursement rate compression

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Growth Deceleration Amid Saturation

According to recent financial disclosures, HCA's year-over-year revenue growth has decelerated to 4.3% in 2026Q1, down from the double-digit expansion observed in early 2024, suggesting that the company's localized cluster strategy may be encountering natural market saturation limits in its core Texas and Florida hubs.

The transition from double-digit growth to mid-single digits indicates that volume gains are no longer outpacing the inflationary pressures on the cost base. Investors should monitor whether this trend reflects a broader softening in elective procedure demand or if it is a temporary normalization following the post-pandemic surge.

Structural Margin Compression and Volatility

As reported in quarterly filings, HCA experienced a significant gross margin contraction to 15.0% in 2026Q1, a sharp departure from the 41% range maintained throughout 2025, which warrants further investigation into whether this reflects a permanent shift in cost recognition or temporary operational inefficiencies.

The sudden volatility in gross margin reporting suggests potential inconsistencies in how the company accounts for variable labor costs or supplemental payment programs. This compression implies that the company's ability to pass through rising clinical expenses to commercial payors may be reaching a structural ceiling.

Operating Leverage Strained by Costs

Based on the provided income statement data, HCA's operating income remained flat at $2.9B in 2026Q1 despite revenue growth, indicating that the company is currently failing to achieve the operating leverage typically expected from its high-volume, cluster-based hospital model in the current inflationary environment.

The inability to scale operating income alongside revenue suggests that fixed costs and labor expenses are rising in lockstep with top-line gains. This lack of efficiency may indicate that the company is struggling to optimize staffing ratios or that the cost of maintaining its clinical infrastructure is outpacing revenue realization.

Sustainability of Premium Valuation Multiples

Data from recent income statements suggests that HCA's earnings quality may be obscured by lumpy supplemental payments, as evidenced by the erratic EPS growth patterns that swung from -18.5% in 2023Q4 to 44.6% in 2025Q4, raising concerns about the long-term sustainability of current profit margins.

Short-sellers would likely focus on the reliance on non-recurring state-directed payments to bolster operating income, which masks the underlying core operational performance. If these supplemental programs face legislative scrutiny or site-neutral payment reforms, the company's profitability could face a significant and rapid downward adjustment.

HCA — Frequently Asked Questions

Quick answers to the most common questions about buying HCA stock.

What was HCA Healthcare, Inc.'s (HCA) revenue in 2025?

For fiscal year 2025, HCA Healthcare, Inc. (HCA) reported total revenue of $75.60B. This represents a 279.7% increase compared to $19.91B in 1996.

Is HCA Healthcare, Inc. (HCA) profitable?

HCA Healthcare, Inc. (HCA) is profitable, generating $6.78B in net income for the fiscal year ending 2025 with a net profit margin of 9.0%.

What is HCA Healthcare, Inc.'s operating profit margin?

HCA Healthcare, Inc. (HCA) reported an operating income of $11.96B, resulting in an operating profit margin of 15.8%. This margin reflects the operational efficiency of the business before interest and taxes.

What is HCA Healthcare, Inc.'s gross profit and gross margin?

HCA Healthcare, Inc. (HCA) generated $31.37B in gross profit for the year, representing a gross profit margin of 41.5%. This demonstrates the company's core pricing power and production efficiency.